Pfizer's Thelin Withdrawn Due to Fatalities
Following two cases of fatal liver injury, Pfizer has voluntarily withdrawn Thelin from the worldwide market and discontinued all ongoing trials.
Following two cases of fatal liver injury, Pfizer has voluntarily withdrawn Thelin (sitaxentan) from the worldwide market and discontinued all ongoing trials. The drug had been approved in the European Union (EU) , Canada, and Australia for the treatment of pulmonary arterial hypertension (PAH).
The withdrawal was based on a review of emerging safety information from clinical trials and post-marketing reports. Thelin belongs to class of drugs of which liver toxicity is a known complication. As such, the treatment has been contra-indicated in patients with mild to severe hepatic impairment and elevated aminotransferases prior to initiation of treatment. In a press statement, however, Pfizer said, “Given the availability of alternate treatments, Pfizer has concluded that the overall benefit of Thelin no longer outweighs the risk in the general population of PAH patients.”
The company has recommended that no new patients be prescribed Thelin and that current patients be transitioned to alternate therapies as soon as safely possible. In a statement, EMA also added that patients currently taking Thelin are advised not to stop the treatment and to consult their physician to review their treatment at their next scheduled appointment.
Pfizer acquired Thelin after buying Encysive Pharmaceuticals (Houston, TX) in 2008. The treatment was authorized for use in the EU in 2006. On the other side of the Atlantic, however, the US Food and Drug Administration refused to approve the drug on three different occasions because of safety concerns. Pfizer had been trying to alleviate these with new clinical studies, which have now been discontinued.
Navigating Annex 1 for Early Phase Sterile Fill Finish in Clinical Supplies
November 21st 2024Stay compliant with Annex 1 for early phase sterile fill finish processes. Discover how to implement robust contamination control strategies, integrate isolator technology, and conduct integrity testing to meet stringent European Union standards. The guide provides a comprehensive look at key elements such as PUPSIT, critical zone controls, and monitoring and training for aseptic processes.
Why is the PDA Pharmaceutical Microbiology Conference the Hottest Ticket in the Industry?
October 10th 2024Get a glimpse of the power and popularity behind the PDA Pharmaceutical Microbiology Conference from two planning committee members, Julia Marre, PhD (Associate Director, Scientific and Regulatory Affairs at Pocket Naloxone Corp) and Dawn Watson (Executive Director, Global Micro Quality and Sterility Assurance at Merck). This candid conversation reveals why this industry event is so influential…and always sold out! The speakers discuss what makes the PDA Pharmaceutical Microbiology Conference so vital to industry professionals, as well as how to become a part of this dynamic professional community.
Ensuring Quality from the Start: Raw Materials Testing Support
November 21st 2024Raw Materials are the foundation of every biopharma product. Our ultimate guide highlights how our testing support can help you establish purity, identity, and quality standards, ensuring a smooth manufacturing process and adherence to regulatory requirements.
Ensure the Safety of Allogeneic Therapies with Advanced qPCR Testing
November 21st 2024Elevate your viral screening with Eurofins BioPharma Product Testing’s qPCR- based assays. Our advanced testing goes beyond standard screenings to detect even dormant and hard-to-detect pathogens, ensuring comprehensive safety in every stage of the allogeneic therapy pipeline. Protect your products – and your patients- with industry-leading sensitivity and specificity.
